/

Sociétés

En

Non vérifié

Enveda

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéScience

17 communiqués de presse

Voir tous les communiqués de presse

29/09/2026

Événements

Industrie

Science

Médecine - Divers

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Enveda Announces Late-Breaker Oral Presentation of New Mechanistic and Biomarker Data from the Phase 1b Trial of ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, at the Upcoming EADV 2026 Congress

Source

Émetteur

1.00

0

23/09/2026

Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century

Source

Émetteur

1.00

0

15/09/2026

Technique

Science

Logiciels

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Contrats et appels d'offre

Industrie

Enveda Is Launching the Next AlphaFold Contest. This Time, to Solve the Structures of 90% of Biological Molecules That No One Can Identify.

Source

Émetteur

1.00

0

18/08/2026

Multimédia

Industrie

Santé

Fitness/Bien-être

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise

Source

Émetteur

1.00

0

23/07/2026

Multimédia

Événements

Industrie

Biotechnologie

Industrie pharmaceutique

Santé

Médecine - Divers

Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV

Source

Émetteur

1.00

0

15/04/2026

Marché du travail

Santé

Technique

Science

Industrie pharmaceutique

Biotechnologie

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

Source

Émetteur

1.00

0

31/03/2026

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

Source

Émetteur

1.00

0

23/12/2025

Science

Technique

Hygiène alimentaire

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Santé

Industrie

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

Source

Émetteur

1.00

0

17/12/2025

Marché du travail

Industrie

Science

Technique

Hygiène alimentaire

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Santé

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy

Source

Émetteur

1.00

0

09/12/2025

Industrie

Hygiène alimentaire

Technologies de l'Information

Technique

Industrie pharmaceutique

Santé Publique

Biotechnologie

Médecine - Divers

Science

Logiciels

Santé

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0